Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Queensland Health
Deloitte
Covington
Harvard Business School
Baxter
Medtronic
US Army
QuintilesIMS
Chinese Patent Office

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,293,756

« Back to Dashboard

Which drugs does patent 8,293,756 protect, and when does it expire?

Patent 8,293,756 protects TASIGNA and is included in one NDA.

This patent has forty patent family members in thirty countries.
Summary for Patent: 8,293,756
Title:Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
Abstract: A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.
Inventor(s): Bruneau; Nathalie (Cran-Gevrier, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:12/442,544
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process; Use;

Drugs Protected by US Patent 8,293,756

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-002 Jun 17, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-001 Oct 29, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,293,756

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06121371Sep 27, 2006
PCT Information
PCT FiledSeptember 25, 2007PCT Application Number:PCT/EP2007/060165
PCT Publication Date:April 03, 2008PCT Publication Number: WO2008/037716

Non-Orange Book US Patents Family Members for Patent 8,293,756

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,501,760 Pharmaceutical compositions comprising nilotinib or its salt ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,293,756

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 062980 ➤ Try a Free Trial
Australia 2007301977 ➤ Try a Free Trial
Brazil PI0719438 ➤ Try a Free Trial
Canada 2662571 ➤ Try a Free Trial
Chile 2007002766 ➤ Try a Free Trial
Hong Kong 1133193 ➤ Try a Free Trial
Spain 2556625 ➤ Try a Free Trial
European Patent Office 3009128 ➤ Try a Free Trial
European Patent Office 2068839 ➤ Try a Free Trial
European Patent Office 1923053 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
AstraZeneca
Colorcon
Cerilliant
Cipla
Fuji
McKesson
McKinsey
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot